The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.

Study participants will be followed up, under existing protocol derived from a study protocol developed by the "Union internationale contre les maladies respiratoires" and carried out already in 9 Africans countries. Participants will be hospitalised for at least four month, period which they will be given treatments, assessed for adverse events, monitored for TB-MR strains using culture techniques, at the monthly basis. If patients found with negative sputum culture at month four they will be dischrged from the hospital, and then treated four an additional five montns and then follow up, clinically and biologically for an additional six months before being declared as cured.

Inclusion criteria:

• Aged 15 years and above
• Never been treated with second line anti-TB drugs for more than one month,
• Give written consent to participate
• Agree to be hospitalised for at least four months in specialised healthcare
• Willing to adhere to ambulatory directly observed treatment by a healthcare worker;

Exclusion criteria:

• Pregnant during inclusion process
• Presented with altered clinical status condition as judged by the clinician
• Knowing of history of hypersensitivity reaction to any of the drugs to be used
• Baseline ECG does not show a QT space superior to 500ms
• Refusal to participate into study.

study population will consist of all consecutive patients with bacteriologically proven MDR-TB who fulfil the inclusion criteria .